Piotr Smolewski Selected Research

Piotr Smolewski Research Topics

Disease

34	Neoplasms (Cancer) 10/2020 - 05/2004
20	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 02/2022 - 05/2003
9	Lymphoma (Lymphomas) 06/2021 - 05/2004
8	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 12/2004
8	Hematologic Neoplasms (Hematological Malignancy) 01/2019 - 07/2003
7	Multiple Myeloma 02/2021 - 08/2008
6	Leukemia 09/2009 - 01/2002
5	Hodgkin Disease (Hodgkin's Disease) 01/2022 - 01/2015
5	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 05/2019 - 05/2004
5	Breast Neoplasms (Breast Cancer) 12/2018 - 10/2011
3	Systemic Lupus Erythematosus (Libman-Sacks Disease) 10/2017 - 07/2004
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 11/2016 - 12/2009
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2015 - 12/2013
3	Essential Thrombocythemia 12/2012 - 12/2009
2	Febrile Neutropenia 01/2022 - 01/2018
2	T-Cell Lymphoma (Lymphoma, T Cell) 06/2021 - 01/2017
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021 - 01/2015
2	Disease Progression 05/2018 - 07/2006
2	Necrosis 06/2013 - 11/2002
2	Thrombosis (Thrombus) 06/2010 - 12/2009
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 02/2008 - 11/2005
2	Acute Promyelocytic Leukemia 05/2002 - 01/2002
1	Second Primary Neoplasms (Neoplasms, Second) 01/2022
1	Drug-Related Side Effects and Adverse Reactions 01/2021
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 10/2020
1	Anemia 01/2020
1	Hypercalcemia (Milk Alkali Syndrome) 01/2020
1	Renal Insufficiency (Renal Failure) 01/2020
1	Amyloidosis 05/2019
1	Immunoglobulin Light-chain Amyloidosis 05/2019
1	Waldenstrom Macroglobulinemia (Macroglobulinemia) 05/2019
1	Hairy Cell Leukemia 01/2019

Drug/Important Bio-Agent (IBA)

14	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2002
12	Pharmaceutical PreparationsIBA 01/2017 - 12/2004
11	Monoclonal AntibodiesIBA 01/2021 - 05/2004
8	Cladribine FDA LinkGeneric 01/2019 - 05/2003
8	Rituximab (Mabthera)FDA Link 05/2018 - 05/2004
5	Antineoplastic Agents (Antineoplastics)IBA 01/2018 - 09/2006
4	Phosphotransferases (Kinase)IBA 02/2022 - 06/2006
4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 01/2018
4	Vinblastine (Vinblastine Sulfate)FDA Link 01/2022 - 01/2018
4	Bleomycin (Blenoxane)FDA LinkGeneric 01/2022 - 01/2018
4	Brentuximab VedotinIBA 01/2022 - 01/2018
4	Dacarbazine (DIC)FDA LinkGeneric 01/2022 - 01/2018
4	Bortezomib (Velcade)FDA Link 02/2021 - 12/2006
4	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2021 - 06/2006
4	CaspasesIBA 01/2021 - 11/2002
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 05/2018 - 05/2003
3	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 01/2017
3	Proteasome InhibitorsIBA 02/2021 - 05/2019
3	Inhibitor of Apoptosis ProteinsIBA 01/2021 - 02/2008
3	Clofarabine (Clolar)FDA Link 12/2018 - 01/2014
3	ranpirnase (Pannon)IBA 07/2014 - 02/2010
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2013 - 06/2010
2	Agammaglobulinaemia Tyrosine KinaseIBA 02/2022 - 01/2021
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2022 - 01/2018
2	idelalisibIBA 01/2021 - 10/2020
2	Protein Isoforms (Isoforms)IBA 10/2020 - 12/2006
2	CytokinesIBA 01/2020 - 07/2004
2	retinoic acid receptor betaIBA 12/2018 - 01/2014
2	PhytochemicalsIBA 12/2018 - 01/2015
2	Toll-Like Receptors (Toll-Like Receptor)IBA 10/2017 - 01/2014
2	Cytotoxins (Cytolysins)IBA 01/2017 - 03/2012
2	Cytostatic AgentsIBA 01/2016 - 02/2010
2	CD20 AntigensIBA 01/2016 - 05/2004
2	Immunomodulating AgentsIBA 09/2015 - 01/2015
2	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 01/2015 - 09/2014
2	SurvivinIBA 01/2015 - 02/2008
2	SMIP-016IBA 10/2014 - 12/2009
2	fludarabineIBA 01/2014 - 12/2004
2	DNA (Deoxyribonucleic Acid)IBA 01/2014 - 11/2002
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 12/2009 - 08/2008
2	Etodolac (Lodine)FDA LinkGeneric 08/2008 - 12/2006
2	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 09/2006 - 11/2005
2	Purine NucleosidesIBA 01/2005 - 12/2004
2	Retinoic Acid Receptor alphaIBA 05/2002 - 01/2002
2	promyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinIBA 05/2002 - 01/2002
1	Messenger RNA (mRNA)IBA 02/2021
1	duvelisibIBA 01/2021
1	venetoclaxIBA 01/2021
1	ibrutinibIBA 01/2021
1	acalabrutinibIBA 01/2021
1	NF-kappa B (NF-kB)IBA 01/2021
1	Carrier Proteins (Binding Protein)IBA 01/2021
1	MicroRNAs (MicroRNA)IBA 09/2020
1	Interleukin-8 (Interleukin 8)IBA 01/2020
1	Hemoglobins (Hemoglobin)IBA 01/2020
1	ChemokinesIBA 01/2020
1	CalciumIBA 01/2020
1	ixazomibIBA 05/2019
1	Lenalidomide (CC 5013)FDA Link 05/2019
1	Dexamethasone (Maxidex)FDA LinkGeneric 05/2019
1	Investigational DrugsIBA 05/2019

Therapy/Procedure

16	Therapeutics 01/2022 - 05/2004
10	Drug Therapy (Chemotherapy) 06/2021 - 09/2006
3	Immunotherapy 01/2018 - 01/2015
2	Hematopoietic Stem Cell Transplantation 08/2014 - 09/2013
1	Transplantation 01/2022
1	Oral Administration 05/2019
1	Stem Cell Transplantation 05/2019